MENU
+Compare
LCTX
Stock ticker: ASE
AS OF
Oct 17 closing price
Price
$1.65
Change
-$0.05 (-2.94%)
Capitalization
376.79M

LCTX Lineage Cell Therapeutics Forecast, Technical & Fundamental Analysis

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases... Show more

LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for LCTX with price predictions
Oct 17, 2025

Aroon Indicator for LCTX shows an upward move is likely

LCTX's Aroon Indicator triggered a bullish signal on October 17, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 170 similar instances where the Aroon Indicator showed a similar pattern. In of the 170 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in of 216 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for LCTX moved out of overbought territory on October 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 67 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on October 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LCTX as a result. In of 115 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LCTX turned negative on October 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LCTX broke above its upper Bollinger Band on September 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.788) is normal, around the industry mean (24.226). P/E Ratio (0.000) is within average values for comparable stocks, (54.529). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (33.445) is also within normal values, averaging (349.660).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

LCTX is expected to report earnings to fall 81.31% to -2 cents per share on November 05

Lineage Cell Therapeutics LCTX Stock Earnings Reports
Q3'25
Est.
$-0.02
Q2'25
Missed
by $0.10
Q1'25
Beat
by $0.01
Q4'24
Beat
by $0.01
Q3'24
Beat
by $0.02
The last earnings report on August 12 showed earnings per share of -12 cents, missing the estimate of -2 cents. With 1.53M shares outstanding, the current market capitalization sits at 376.79M.
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2173 Salk Avenue
Phone
+1 442 287-8990
Employees
75
Web
https://www.lineagecell.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LRRIF0.230.01
+3.51%
Lion Rock Resources Inc.
ADDHY16.480.54
+3.38%
Addtech AB
LRLCY91.631.81
+2.02%
L'Oreal Co.
WIPKF29.690.10
+0.33%
Winpak Ltd.
NXCLF1.25N/A
N/A
Lifull Co Ltd

LCTX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LCTX
1D Price
Change %
LCTX100%
-2.94%
MDGL - LCTX
43%
Loosely correlated
-0.73%
ELVN - LCTX
34%
Loosely correlated
-1.56%
MGNX - LCTX
33%
Loosely correlated
-2.37%
PYXS - LCTX
33%
Loosely correlated
+0.30%
AXON - LCTX
33%
Loosely correlated
+2.84%
More